| Durvalumab in frail and elder patients with stage four NSCLC- the DURATION trial |
|
|
|
Poster |
2018 |
|
Thorakale Onkologie
|
|
|
| oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Durvalumab-in-frail-and-elder-patients-with-stage-four-NSCLC-the-DURATION-trial |
|
|
| Molecular testing, frequency of molecular alterations and first-line treatment of patients with non-small cell lung carcinoma (NSCLC) in Germany. First results from the prospective German Registry CRISP (AIO-TRK-0315) |
|
|
|
Abstract |
2018 |
|
Thorakale Onkologie
|
|
|
| ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e21236 |
|
|
| G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey |
|
|
|
Vollpublikation |
2018 |
|
Supportive Therapie
|
|
|
| www.ncbi.nlm.nih.gov/pubmed/30374765 |
|
|
| Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer – the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. |
|
|
| BMC Cancer 18: 1298 |
|
2018 |
|
Pankreaskarzinom
|
|
|
| doi.org/10.1186/s12885-018-5183-y |
|
|
| A composite liquid biomarker for non-invasive diagnosis of resectable pancreatic ductal adenocarcinoma |
|
|
|
Poster |
2018 |
|
Pankreaskarzinom
|
|
|
| oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/A-composite-liquid-biomarker-for-non-invasive-diagnosis-of-resectable-pancreatic-ductal-adenocarcinoma |
|
|
| Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- versus FOLFIRINOX-based induction chemotherapy: Interim results of a randomized phase II AIO trial (NEOLAP) |
|
|
|
Abstract |
2018 |
|
Pankreaskarzinom
|
|
|
| ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.348 |
|
|
| Checkpoint-Inhibitoren als Zweitlinientherapie bei älteren Patienten mit fortgeschrittenem Plattenepithelkarzinom des Oesophagus |
|
|
|
Sonstige |
2018 |
|
Ösophagus-/Magenkarzinome
|
|
|
| link.springer.com/article/10.1007/s12312-018-0494-0 |
|
|
| Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): The randomized phase II INTEGA trial (AIO STO 0217) |
|
|
|
Poster |
2018 |
|
Ösophagus-/Magenkarzinome
|
|
|
| oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Ipilimumab-or-FOLFOX-in-combination-with-Nivolumab-and-Trastuzumab-in-previously-untreated-HER2-positive-locally-advanced-or-metastastic-EsophagoGastric-Adenocarcinoma-EGA-the-randomized-phase-2-INTEGA-trial-AIO-STO-0217 |
|
|
| Randomised phase II trial to investigate catumaxomab (anti-EpCAM×anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer |
|
|
|
Vollpublikation |
2018 |
|
Ösophagus-/Magenkarzinome
|
|
|
| www.nature.com/articles/s41416-018-0150-6 |
|
|
| Intraperitoneal immunotherapy with the bispecific anti-EpCAM x anti-CD3 directed antibody catumaxomab for patients with peritoneal carcinomatosis from gastric cancer: Final results of a randomized phase II AIO trial |
|
|
|
Abstract |
2018 |
|
Ösophagus-/Magenkarzinome
|
|
|
| ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.4 |
|
|
